X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RiVive (naloxone HCl nasal spray) is an FDA approved, over-the-counter (OTC) medication which is indicated for the emergency treatment of opioid overdose.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: RiVive
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
RiVive (naloxone HCl) is a μ opioid receptor antagonist. It is an FDA-approved, over-the-counter medication approved for the emergency treatment of opioid overdose.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: RiVive
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
RiVive™ (Naloxone HCl Nasal Spray 3 mg) an opioid antagonist to be available over the counter (OTC) for the emergency treatment of life-threatening opioid overdose.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Rivive
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
Under the agreement, Catalent will manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive™, for the emergency treatment of known or suspected opioid overdose.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Rivive
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Catalent Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 23, 2023
Details:
The proceeds will be used to fund commercial readiness for HRT’s low-cost over-the-counter (OTC) intranasal naloxone spray, tradename RiVive. Naloxone is an opioid antagonist rescue medication used to reverse the effects of a life-threatening opioid overdose.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Rivive
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Purdue Pharma
Deal Size: $29.9 million Upfront Cash: Undisclosed
Deal Type: Financing March 21, 2023
Details:
RiVive is an intranasal formulation of naloxone (3.0 mg) delivered as an atomized spray (0.1 ml) using a standard unit dose system for single administration.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: RiVive
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2022
Details:
Revive (naloxone hydrochloride) is a safe and effective opioid antagonist, originally approved by the FDA in 1971 and has been used for decades by both medical professionals and the lay public to successfully reverse opioid overdoses.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Revive
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
Under its terms, the contract manufacturer will produce Harm Reduction Therapeutics' nasal spray, RiVive™ (3.0mg naloxone), for the emergency treatment of known or suspected opioid overdose.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Revive
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 11, 2022
Details:
The additional funding approved today will help HRT continue its work toward making OTC naloxone nasal spray available to the public. HRT plans to file a New Drug Application for naloxone nasal spray with FDA in 2022.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Revive
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Purdue Pharma
Deal Size: $17.5 million Upfront Cash: Undisclosed
Deal Type: Financing March 23, 2022
Details:
HRT001 is an intranasal formulation of naloxone (3.0 mg) delivered as an atomized spray (0.1 ml) using a standard unit dose system for single administration. Its tentatively approved tradename is RiVive™.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: RiVive
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sage Chemical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
